Skip to main content
Air Liquide
Air Liquide worldwide
Please select

Engineering & Construction

Open

Large projects

Open

Parkinson’s disease

More than just a movement disorder

Over 6 million adults worldwide1 live with Parkinson's disease. This number is growing steadily and is expected to reach over 12.9 million in 20402. Parkinson's disease is a chronic, progressive neurodegenerative disease which appears with the deterioration and loss of neurons in the brain, responsible for progressive disability symptoms.

Over
6 M

people living with Parkinson's disease worldwide

Among EU citizens
51%

that consult specialists are at advanced Parkinson's disease stage (3)

Key symptoms of Parkinson's disease4

While each person living with Parkinson's disease is unique, these are the most frequent symptoms affecting the lives of people living with Parkinson's disease and their caregivers:

  • Motor symptoms such as tremor, rigidity, bradykinesia or slowing of movement, and postural instability, but also difficulty swallowing, chewing or speaking
  • Non-motor symptoms such as pain, anxiety and depression, but also emotional changes, urinary problems or constipation, dementia or other cognitive problems, fatigue and sleeping disorders are also frequent

Need for diagnosis and treatment

At the beginning of  the course of the disease, only symptomatic oral treatments  are available. When significant motor symptoms persist despite optimised oral treatment, advanced therapies (device assisted  therapy) should be considered. Non-motor symptoms should also be considered with additional treatment to better manage the quality of life of people living with Parkinson’s disease5.

A large population is living with Advanced Parkinson's disease and only a small proportion  benefits from device-assisted therapy 

A survey performed in Sweden showed that 3 out of 4 patients had heard of advanced treatment options but are denied6 treatment  Late diagnosis and late treatment of advanced Parkinson's disease with appropriate device-assisted therapy has severe long-term consequences for people living with Parkinson's disease and their caregivers, such as :

  • More time spent in bad motor phases, resulting in falls, choking, and loss of autonomy, as well as increased dependence on caregivers for everyday tasks
  • Significant health and economic burden with a reduction in quality of life for people living with Parkinson's disease and their caregivers

A long-term care pathway7,8

While a disease-modifying treatment does not exist yet for Parkinson's disease, motor and non-motor symptoms can be  managed with the help of prescribed treatment.

Compliance with prescribed therapy and healthy living measures

Managing the treatment of Parkinson’s Disease requires strong care coordination, as many different actors must be integrated.

The main treatment for people with Parkinson's disease is to restore the  supply of dopamine to the brain, starting with oral treatments, with the number of different molecules increasing constantly. When symptoms become difficult to control with  medication alone, device-assisted therapies can be considered, such as surgically implanted deep brain stimulation, continuous intestinal gels or subcutaneous infusion  by pump.

Supportive therapies, such as physiotherapy, or speech and language therapy can also make living with Parkinson's disease easier for patients and caregivers.

In addition, management of non-motor symptoms (depression, anxiety, sleeping disorders, erectile or urinary dysfunction,  sweating, swallowing difficulties, excessive drooling) must be considered.

Our commitment to  improving the care and quality of life of people living with Parkinson's disease and their caregivers

Involved in constantly improving home management for people with Parkinson's disease and their caregivers, Air Liquide Healthcare is a responsible actor in the care pathway for people living with Parkinson's disease requiring device-assisted therapy for improved symptom control, quality of life and autonomy. Adherence (acceptance, compliance, persistence) to the prescribed care plan is central to our mission.

At the service of people living with the disease and their caregivers

Starting with the neurologist's prescription for device-assisted therapy, the home healthcare provider contacts and supports people living with Parkinson's disease and their caregivers in their day-to-day life. Various services are offered to people living with Parkinson's disease and their caregivers:

  • Supply of medical devices and consumables
  • Training and support on  handling and setting-up the device
  • Coaching and personalized support
  • Home visits
  • Contact center support

References:

Dorsey, E. et al. (2018). Global, regional, and national burden of Parkinson's disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology. 17. 10.1016/S1474-4422(18)30295-3.
Dorsey ER, Bloem BR. The Parkinson Pandemic - A Call to Action. JAMA Neurol. 1 janv 2018;75(1):9‑10.
Fasano A, Fung VSC, Lopiano L, Elibol B, Smolentseva IG, Seppi K, et al. Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients. BMC Neurology. 2 avr 2019;19(1):50.
4 https://www.epda.eu.com/about-parkinsons/symptoms/ (consulted April 23, 2021)
5 Kobylecki C. Update on the diagnosis and management of Parkinson’s disease. Clinical Medicine. 1 juill 2020;20 (4):393‑8.
6 Lökk, Johan. « Lack of Information and Access to Advanced Treatment for Parkinson';s Disease Patients ». Journal of Multidisciplinary Healthcare, December 2011, 433. Available at https://doi.org/10.2147/JMDH.S27180.
7 European Parkinson Disease Association, What is Parkinson’s: https://www.epda.eu.com/about-parkinsons/what-is-parkinsons/ (consulted March 23, 2021)
8 National Health Service, UK. Parkinson's Disease Treatment? Available at: https://www.nhs.uk/conditions/parkinsons-disease/treatment/ (consulted March 23, 2021)